Advanced searches left 3/3

Everolimus - U.S. Department of Veterans Affairs

Summarized by Plex Scholar
Last Updated: 07 February 2022

* If you want to update the article please login/register

Activation of EIF4E by Aurora Kinase A Depicts a Novel Druggable Axis in Everolimus-Resistant Cancer Cells.

Experimental Design: We investigated AURKA's involvement in the production of EIF4E, cap-dependent translation, and resistance to mTOR inhibitor in this research. RAD001, a new type of oral gastrointestinal adenocarcinomas, revealing the role of AURKA in the formation of EIF4E and cap-dependent translation. AURKA's cancer cell survival in inherited and intrinsic resistant cell models was reduced by a reduction in tumor cell survival. Our findings show that everolimus-resistant cancer cells are sensitive to alisertib and cap-dependent translation. The AURKA-EIF4E-c-MYC axis, as well as some subgroups of cancers that have overexpression of AURKA and deactivation of EIF4E and c-MYC, according to an innovative therapeutic approach, targeting the AURKA-EIF4E-C-MYC axis using alisertib is a novel therapeutic approach that may be adapted to everolimus-resistant tumors and/MYC axis and/MYC axis and axis axis, axis of MYC axis of cancers of AURKA and/MYC axis and activation of EIF4EI-MYC axis of AURKA-MYC axis that can be used in the AURKA-MYC axis and c-MYC axis that may besiegetib, c-MYC axis, EIF4EIF4EIF.

Source link: https://doi.org/10.1158/1078-0432.CCR-16-2141

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions